Pfizer - AI Stock Analysis

Analysis generated January 9, 2026

Pfizer Inc. (NYSE: PFE) is a global pharmaceutical corporation specializing in the development and production of medications and vaccines. With a rich history dating back to 1849, Pfizer has established itself as a leader in innovative healthcare solutions. The company’s portfolio includes some of the world's best-selling medicines and vaccines, including prominent products like the COVID-19 vaccine developed in partnership with BioNTech.

Fundamental Analysis

Examining Pfizer’s recent financial performance offers insights into its operational health and future potential. In the most recent quarter, Pfizer reported a revenue of $16.7 billion. This marks a 13.66% increase compared to the previous quarter, suggesting positive growth momentum. However, year-over-year revenue was down by 5.92%, which could raise concerns about long-term sustainability.

The net income for the last quarter stood at $3.54 billion, an impressive gain of 21.68% from the previous quarter. Despite this, the figure represents a 20.84% drop compared to the same quarter last year. The EBITDA was $5.65 billion, up by 6.11% quarter-over-quarter but down 22.13% year-over-year. Collectively, these figures indicate strong recent growth but also reveal potential challenges when compared to annual performance.

From a valuation perspective, Pfizer currently has a Price-to-Earnings (P/E) ratio of 14.7. This ratio is within a normal range, indicating that the stock is neither particularly undervalued nor overvalued.

Technical Analysis

Today’s stock price of Pfizer is $25.55, representing a 0.87% increase over the past month. This positive short-term trend aligns with a 2.57% increase over the past year, suggesting a bullish long-term trend as well. The current Simple Moving Average (SMA10) is $25.21, slightly above the previous SMA10 of $25.15, which could indicate a sustained upward trend in the stock price.

The Relative Strength Index (RSI) is at 46.1, which is in neutral territory. This suggests that the stock is neither overbought nor oversold, presenting a balanced view of market sentiment for Pfizer’s shares at the moment.

Alternative Data Analysis

In terms of job postings, Pfizer has 563 open positions, a 9% decrease over the last couple of months. This reduction could indicate cost-saving initiatives, possibly hinting at a strategic move to improve margins rather than expansion.

Employee sentiment at Pfizer remains neutral, but the number of website visitors has surged by 30% over the past few months to an estimated 3.2 million. This influx of traffic may point to increased customer interest and potential for growth.

On social media, Pfizer maintains a steady presence with 120,000 Instagram followers and 470,000 Twitter followers. Notably, there has been no significant change in Instagram followers, while Twitter followers have decreased by 1%, hinting at a slight decline in public interest.

According to AltIndex’s AI score, which aggregates fundamental, technical, and alternative data, Pfizer has a score of 48, signaling a “hold” recommendation.

Conclusion and Recommendation

Pfizer presents a mixed bag of opportunities and challenges. The recent quarterly growth figures are promising, but year-over-year comparisons show areas of concern. The technical indicators suggest a bullish trend, though the RSI and social media metrics provide neutral to slightly bearish signals.

Alternative data offers a nuanced view: while job postings are down, customer interest appears to be climbing, which could drive future growth. With an AI score of 48, the consensus appears to lean towards holding the stock rather than making aggressive moves.

Based on the provided data, a cautious approach is advisable. Monitoring upcoming quarters for sustained revenue and profit growth could provide a clearer direction for future investment decisions.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.